Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock-Reference-Cited by-同舟云学术

Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock

Published:2023-07 Issue:7 Volume:29 Page:1097-1103
ISSN:1071-9164
Container-title:Journal of Cardiac Failure
language:en
Short-container-title:Journal of Cardiac Failure

Author:

Metra MARCO,CHIONCEL OVIDIU,DAVISON BETH,FILIPPATOS GERASIMOS,MEBAZAA ALEXANDRE,PAGNESI MATTEO,ADAMO MARIANNA,NOVOSADOVA MARIA,PONIKOWSKI PIOTR,SIMMONS PHILLIP,SOFFER JOSEPH,SIMONSON STEVEN,COTTER GAD

Funder

Windtree Therapeutics

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference7 articles.

1. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology;Chioncel;Eur J Heart Fail,2020

2. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association;Van Diepen;Circulation,2017

3. Altered cardiac myocyte Ca regulation in heart failure;Bers;Physiology (Bethesda),2006

4. Precardiogenic shock: a new clinical entity;Singh;Cardiol Rev,2019

5. Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause - the Cardiogenic Shock Score;Beer;Eur J Heart Fail,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors;European Journal of Heart Failure;2024-02

2. Safety and Efficacy of Istaroxime in Patients With Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials;Cureus;2023-06-28